ArticleOncology letters2019
Downregulation of miR-505 promotes cell proliferation, migration and invasion, and predicts poor prognosis in breast cancer.
Article in Oncology letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- RCE-IFE: recursive cluster elimination with intra-cluster feature elimination.PeerJ. Computer science · 2025Article
- Associations of plasma extracellular microRNAs with new-onset breast cancer in the Framingham heart study.American journal of cancer research · 2024Article
- Circular RNAMolecular therapy oncolytics · 2021Article
- A Novel TCGA-Validated, MiRNA-Based Signature for Prediction of Breast Cancer Prognosis and Survival.Frontiers in cell and developmental biology · 2021Article
- lncRNA KTN1‑AS1 promotes glioma cell proliferation and invasion by negatively regulating miR‑505‑3p.Oncology reports · 2020Observational
- Aberrant expression of miR-4728 in patients with non-small cell lung cancer and its regulatory effects on tumor progression in tumor cells.Experimental and therapeutic medicine · 2020Article
- Identification of miR-135b as a novel regulator of TGFβ pathway in gastric cancer.Journal of physiology and biochemistry · 2020Article
- Potential miRNAs for miRNA-Based Therapeutics in Breast Cancer.Non-coding RNA · 2020Review
- miR-505 inhibits proliferation of osteosarcoma via HMGB1.FEBS open bio · 2020Article
- lncRNA PART1 Promotes Breast Cancer Cell Progression by Directly Targeting miR-4516.Cancer management and research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
microRNAs are involved in the tumor progression of various cancer types. The present study aimed to determine the prognostic significance of microRNA-505 (miR-505) in patients with breast cancer and investigate the functional role of miR-505 in BCa progression. The expression of miR-505 was estimated using reverse transcription-quantitative polymerase chain reaction. Kaplan-Meier survival curves and Cox regression analysis were used to evaluate the prognostic value of miR-505 in patients with BCa. Cell experiments were performed to assess the biological function of miR-505 during BCa progression. A significant downregulated expression level of miR-505 was observed in BCa tissues and cells compared with the corresponding controls (P<0.001). The expression of miR-505 was significantly associated with distant metastasis status (P=0.013) and Tumor-Node-Metastasis staging (P=0.002). Furthermore, the overall survival time was significantly shorter for patients with low miR-505 expression compared with those with high miR-505 expression (P<0.001). In addition, miR-505 was identified as an independent prognostic factor for BCa. The results of cell experiments revealed that an overexpression of miR-505 could significantly inhibit BCa cell proliferation, migration and invasion, whereas a downregulation of miR-505 significantly enhanced BCa cell proliferation, migration and invasion (P<0.05). In summary, all data indicated that a low miR-505 expression level is associated with a poor prognosis for patients with BCa and promotes tumor cell proliferation, migration and invasion. Therefore, the aberrant expression of miR-505 may serve as a therapeutic target for BCa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.